Matching articles for "Lagevrio"
COVID-19 Update: Bebtelovimab EUA Withdrawn (online only)
The Medical Letter on Drugs and Therapeutics • December 26, 2022; (Issue 1666)
The FDA has withdrawn its Emergency Use
Authorization (EUA) of the investigational anti-SARS-CoV-2 monoclonal antibody bebtelovimab
(LY-CoV1404 – Lilly) for treatment of COVID-19.
Bebtelovimab is not...
The FDA has withdrawn its Emergency Use
Authorization (EUA) of the investigational anti-SARS-CoV-2 monoclonal antibody bebtelovimab
(LY-CoV1404 – Lilly) for treatment of COVID-19.
Bebtelovimab is not expected to retain activity
against the Omicron variants BQ.1 and BQ.1.1, which
currently cause the majority of COVID-19 cases in all
regions of the US.
COVID-19 Update: Resistance to Bebtelovimab (online only)
The Medical Letter on Drugs and Therapeutics • November 28, 2022; (Issue 1664)
The FDA has warned that the investigational anti-SARS-CoV-2 monoclonal antibody bebtelovimab
is not expected to retain activity against the
Omicron variants BQ. and BQ.1.1.1 Bebtelovimab
(LY-CoV1404 –...
The FDA has warned that the investigational anti-SARS-CoV-2 monoclonal antibody bebtelovimab
is not expected to retain activity against the
Omicron variants BQ. and BQ.1.1.1 Bebtelovimab
(LY-CoV1404 – Lilly) is available under an FDA
Emergency Use Authorization (EUA) for IV treatment
of mild to moderate COVID-19 in high-risk patients
≥12 years old who weigh ≥40 kg for whom alternative
treatment options are unavailable or inappropriate.
The drug remains authorized for use in all regions
of the US.
COVID-19 Update: NIH Recommends Against Ivermectin
The Medical Letter on Drugs and Therapeutics • June 13, 2022; (Issue 1652)
On April 29, the NIH recommended against use of the antiparasitic drug ivermectin for treatment of COVID-19 outside of a clinical trial. The recommendation was made because recent randomized, placebo-controlled...
On April 29, the NIH recommended against use of the antiparasitic drug ivermectin for treatment of COVID-19 outside of a clinical trial. The recommendation was made because recent randomized, placebo-controlled trials of ivermectin have produced negative results and because alternative drugs that have been shown to be effective for treatment of COVID-19 are available.
COVID-19 Updates
The Medical Letter on Drugs and Therapeutics • April 18, 2022; (Issue 1648)
The FDA has expanded the Emergency Use Authorizations
(EUAs) for the mRNA COVID-19 vaccines
manufactured by Pfizer-BioNTech (Comirnaty) and
Moderna (Spikevax) to allow for their use as a second
booster dose...
The FDA has expanded the Emergency Use Authorizations
(EUAs) for the mRNA COVID-19 vaccines
manufactured by Pfizer-BioNTech (Comirnaty) and
Moderna (Spikevax) to allow for their use as a second
booster dose ≥4 months after a first booster dose in
adults ≥50 years old and in persons aged ≥12 years
(Pfizer) or ≥18 years (Moderna) who have undergone
solid organ transplantation or have a condition that
compromises the immune system to a similar extent.